1689 10 20655 https://socictopen.socict.org/files/original/c6f0b3a70dc5e54b589ace3413ae6d1d.pdf 4a31a1623c739098ff692a6d4c39a19a Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource How Are We Facing It? Dispatches From Pathology Residents in a COVID-19 Lombardy Hospital Creator An entity primarily responsible for making the resource Piergiuseppe Colombo, Massimo Roncalli, Miriam Cieri, Cesare Lancellotti, Camilla De Carlo, Marina Valeri, Vincenzo Belsito Description An account of the resource At the end of February, the Italian National Health Service reported a hot spot of Coronavirus disease in the Lombardy region. COVID-19 is a highly pathogenic viral infection which poses some challenges for healthcare workers. Indeed, Pathology Departments are involved in reorganizing samples' management, from their delivery until their processing, according to National and WHO guidelines. Since Lombardy has been declared COVID-19 hot spot, due to decreasing number of surgical procedures, our Department adopted a policy to reduce personnel, allowing pathologists to work remotely during the outbreak. Lacking clear information about viral load on tissue samples, all human specimens must be considered potentially infectious, as well as patients during post-mortem examinations, and clinical information on COVID-19 status is mandatory. It is also important that Pathology staff receive an adequate training, and adherence to rules should be always accompanied by common sense. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Autopsy, pathology, healthcare worker, resident, Smart Work, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.3389/fpubh.2020.00259 Source A related resource from which the described resource is derived Frontiers in Public Health Publisher An entity responsible for making the resource available Frontiers Media S.A. Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Public aspects of medicine https://socictopen.socict.org/files/original/1c178b51ae13d3ac05b94490eec9b593.pdf 56e9acc94d5a93c5b7a1d6b703fa6bbb Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Towards reduction in bias in epidemic curves due to outcome misclassification through Bayesian analysis of time-series of laboratory test results: case study of COVID-19 in Alberta, Canada and Philadelphia, USA Creator An entity primarily responsible for making the resource Igor Burstyn, Paul Gustafson, Neal D. Goldstein Description An account of the resource Abstract Background Despite widespread use, the accuracy of the diagnostic test for SARS-CoV-2 infection is poorly understood. The aim of our work was to better quantify misclassification errors in identification of true cases of COVID-19 and to study the impact of these errors in epidemic curves using publicly available surveillance data from Alberta, Canada and Philadelphia, USA. Methods We examined time-series data of laboratory tests for SARS-CoV-2 viral infection, the causal agent for COVID-19, to try to explore, using a Bayesian approach, the sensitivity and specificity of the diagnostic test. Results Our analysis revealed that the data were compatible with near-perfect specificity, but it was challenging to gain information about sensitivity. We applied these insights to uncertainty/bias analysis of epidemic curves under the assumptions of both improving and degrading sensitivity. If the sensitivity improved from 60 to 95%, the adjusted epidemic curves likely falls within the 95% confidence intervals of the observed counts. However, bias in the shape and peak of the epidemic curves can be pronounced, if sensitivity either degrades or remains poor in the 60–70% range. In the extreme scenario, hundreds of undiagnosed cases, even among the tested, are possible, potentially leading to further unchecked contagion should these cases not self-isolate. Conclusion The best way to better understand bias in the epidemic curves of COVID-19 due to errors in testing is to empirically evaluate misclassification of diagnosis in clinical settings and apply this knowledge to adjustment of epidemic curves. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource uncertainty, Simulation, Sensitivity, epidemic, under-diagnosis, Bias analysis Identifier An unambiguous reference to the resource within a given context DOI: 10.1186/s12874-020-01037-4 Source A related resource from which the described resource is derived BMC Medical Research Methodology Publisher An entity responsible for making the resource available BMC Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine (General) https://socictopen.socict.org/files/original/482ce44394efad9e19fa3b6ba6e26eca.pdf 23a71690252722cfd8b32cf9883568f9 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource A Review on Coronavirus Disease (COVID-19) and What is Known about it Creator An entity primarily responsible for making the resource Sara Taheri Description An account of the resource Pandemic of New Coronavirus 2019 is becoming a health crisis in the world. The various aspects of the virus are still unknown. This study aims to introduce general aspects of the virus. This study is a narrative review that reviews the available literatures on the internet. Articles published from January 1, 2020 to March 3, 2020 were searched using the keywords COVID-19 and New Coronavirus 2019. The search was mainly conducted through PubMed and Google Scholar, using the keywords COVID-19 and New Coronavirus 2019. We also used Regular Google's search engine to gather news and background information. Prevalence, control, and prevention aspects of the disease were reviewed and presented. The study showed that the ways of transmitting the Covid 19 virus are through respiratory droplets and direct contact with the virus-containing secretions. The causes of the overwhelming prevalence of this disease can be attributed to its high incubation period and its transmission in the asymptomatic, mild, or pre-emergent periods. The study also found symptoms of the virus in people with chronic diseases such as cardiovascular disease, diabetes, cancer, hypertension and chronic respiratory illnesses, and the risk of the virus increases with age and a definite cure has not been discovered yet. The results showed that the epidemic of the new virus will continue for three months and can be prevented by the methods of prevention and management of the factors influencing its transmission. Suggested ways to treat the disease are also being investigated. Currently, the only way to control Coronavirus 19 is to maintain personal hygiene, boost immunity system of body and avoid staying in crowded places. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Epidemiology, Prevalence, Control and prevention, COVID-19, coronavirus 2019 Identifier An unambiguous reference to the resource within a given context DOI: Source A related resource from which the described resource is derived Taṣvīr-i salāmat Publisher An entity responsible for making the resource available Tabriz University of Medical Sciences Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine (General) https://socictopen.socict.org/files/original/a15bd31a3d6b213e7bb20a2c44358674.pdf 0890acaeddfd1b78e4333bb83c8def0a Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Principles, Utility and Limitations of Pulse Oximetry in Management of COVID-19 Creator An entity primarily responsible for making the resource Lok Raj Joshi Description An account of the resource Pulse oximetry is an essential component of the standard care of COVID-19 patients. In the context of the spreading COVID-19 pandemic for which no targeted therapy or vaccines are yet available, early identification of the severe cases or cases with high risk of severe disease and appropriate supportive treatment are of paramount importance to save lives. Pulse oximetry is a cheap, fast, easy to use, noninvasive, painless and accurate tool that allows real-time monitoring of hypoxemia. As the primary target of the disease is the respiratory system pulse oximetry provides an unparalleled way to assess the severity of the disease, guide supportive therapies and monitor the clinical status and response to treatment with greater benefits in the low-resource settings. All settings from the quarantine facilities at the ground level to the ICUs in the highest level hospitals can utilize it to achieve their goals. To get the best of this tool, it needs to be used properly and the findings interpreted carefully. Role of basic understanding of the physiological principles and technology behind its use and awareness of its limitations cannot be overemphasized. The pulse oximetry readings are interpreted in the context of blood hemoglobin concentration, tissue perfusion, arterial blood carbon dioxide concentration and oxygen supplementation status. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource pulse oximetry, Nepal, Utility, limitations, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.22502/jlmc.v8i1.356 Source A related resource from which the described resource is derived Journal of Lumbini Medical College Publisher An entity responsible for making the resource available Lumbini Medical College Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine (General) https://socictopen.socict.org/files/original/f6ca87f787e16c708312ee801d7d9672.pdf 7f6cb400e9b0e5e89381034480f60059 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial Creator An entity primarily responsible for making the resource Chi Zhang, Hong Zhao, Zhao Wu, Jia-wen Li, Guiqiang Wang Description An account of the resource Abstract Objectives A variety of possible mechanisms can make the nucleic acid test of patients who meet the discharge conditions positive again, including reinfection, reactivation of the original virus, lack of strict discharge criteria, new infection, and so on. Different reasons will correspond to different prevention and control measures. We will enroll patients who are discharged after treatment, whose nucleic acid test has changed from negative to positive during the screening visit, regardless of the severity of the symptoms, to investigate the mechanism, clinical outcome and therapeutic efficacy with Favipiravir patients with Corona virus Disease 2019. Favipiravir is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase, it has been used for treatment of some life-threatening infections such as Ebola virus, Lassa virus and rabies. Its therapeutic efficacy has been proven in these diseases. Trial design This is a multi-center, two arm, open label, parallel group, randomized controlled trial. Participants Eligibility criteria: Inclusion criteria: 1. Adults 18 to 80 years, male or female. 2. After the first diagnosis and treatment of COVID-19, the nucleic acid test of respiratory specimens such as sputum or nasopharyngeal swabs, has been negative for two consecutive times (sampling time interval of at least 24 hours), in accordance with the COVID-19’s diagnosis and treatment Plan (7th Edition), discharged. 3. During screening visit (follow-up after discharge), The nucleic acid test of COVID-19 is positive in any one of the following samples: sputum, throat swabs, blood, feces or other specimens. Regardless of whether or not they had symptoms and the severity of symptoms. 4. Volunteer to participate in the research and sign the Informed Consent Form. Exclusion Criteria: 1. Allergic to Favipiravjr; 2. Pregnant or lactating women 3. Uncontrolled diseases of the blood and cardiovascular system, liver or kidney. 4. History of mental disorders, drug abuse or dependence; 5. Researchers consider it inappropriate for adults to participate; 6. Participating in other clinical studies. Loss to Follow up: Cases that do not complete the clinical trial program will be regarded as lost to follow up. Including the withdrawal of patients by themselves (such as poor compliance, etc.), or the withdrawal of patients ordered by the researcher (those who need other drugs which affect the judgment of the curative effect, and those who need to stop taking drugs for severe adverse events) Study setting: The participating hospitals are some of the designated hospitals that have been or may be admitting patients who meet the eligibility criteria, mainly in Hubei, Shenzhen, Anhui and Beijing. Participants will be recruited from these 15 hospitals: Wuhan Pulmonary Hospital, Hubei; Jinyintan Hospital of Wuhan, Hubei; Ezhou Central Hospital, Hubei; The Second People's Hospital of Fuyang, Anhui; The First Affiliated Hospital of USTC, Anhui; Beijing Youan Hospital, Beijing; Capital Medical University Beijing Institute of Hepatology, Beijing; Ezhou Hospital of Traditional Chinese Medicine, Hubei; Zhongnan Hospital of Wuhan University, Hubei; The Fifth Hospital of ShiJiazhuang, Hebei; Jinan Infectious Diseases Hospital, Shandong; Public Health Clinical Center of Chengdu, Sichuan; Wuxi No.5 People’s Hospital, Jiangsu; The Third People’s Hospital of Shenzhen, Guangdong; The First Affiliated Hospital of Bengfu Medical College, AnHui. Intervention and comparator Favipiravir group (experimental): Favipiravir 1600mg each dose, twice a day on the 1st day; 600mg each dose, twice a day from the 2nd to the 7th day, Oral administration, the maximum number of days taken will be no more than 14 days plus routine treatment for COVID-19. Regular treatment group (control): Treatments other than Antiviral drugs can be given. Routine treatment for patients with the corona virus will be administered, this includes oxygen therapy, drugs that reduced phlegm and relieve cough, including thymosin, proprietary Chinese medicine, etc. Main outcomes Primary Outcome Measures: Viral nucleic acid test negative [Time Frame: 5 months]: Subjects who tested negative for nucleic acid from sputum or nasopharyngeal swabs for two consecutive times (sampling time interval of at least 24 hours). Secondary Outcome Measures: Clinical cure [Time Frame: 5 months]: 1. Body temperature returned to normal for more than 3 days; 2. Lung image improved. 3. Clinical manifestation improved; 4. The viral nucleic acid test of respiratory specimens was negative for two consecutive times (sampling time interval of at least 24 hours). Randomization The central randomization system (Interactive Web Response Management System), will be used to randomly divide the subjects into the experimental group and the control group according to the ratio of 2:1. In this study, block randomization will be used, in blocks of 6. Blinding (masking) This is an open label trial. Trial participants, investigators, care givers, outcome assessors, and date analysts are not blinded to group assignment. Numbers to be randomised 210 patients are expected to be enrolled and allocated according to the ratio of 2 (Favipiravir group, n=140): 1(regular treatment group, n=70). Trial Status Protocol version number 3.0, 10th April 2020 First Patient, first visit 17th March 2020; recruitment end date anticipated June 1, 2020. Trial registration ClinicalTrials.gov, NCT04333589 , April 3, 2020. Registered April 3, 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Randomised controlled trial, protocol, favipiravir, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.1186/s13063-020-04430-y Source A related resource from which the described resource is derived Trials Publisher An entity responsible for making the resource available BMC Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine (General) https://socictopen.socict.org/files/original/3f3fcd3daea7667e0bda8d8dce22c74e.pdf 013759ef0e3ff379704b8c2e538d249d Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial Creator An entity primarily responsible for making the resource Bart Lambrecht, Karel Van Damme, Marnik Vuylsteke, Stefaan Vandecasteele, Cedric Bosteels, Bastiaan Maes, Stefanie Vermeersch, Elisabeth De Leeuw, Jozefien Declercq, Anja Delporte, Bénédicte Demeyere, Joren Willaert, Laura Bollé, Yuri Vanbiervliet, Jana Decuypere, Frederick Libeer, Isabelle Peene Description An account of the resource Abstract Objectives The hypothesis of the proposed intervention is that Granulocyte-macrophage colony-stimulating factor (GM-CSF) has profound effects on antiviral immunity, and can provide the stimulus to restore immune homeostasis in the lung with acute lung injury post COVID-19, and can promote lung repair mechanisms, that lead to a 25% improvement in lung oxygenation parameters. Sargramostim is a man-made form of the naturally-occurring protein GM-CSF. Trial design A phase 4 academic, prospective, 2 arm (1:1 ratio), randomized, open-label, controlled trial. Participants Patients aged 18-80 years admitted to specialized COVID-19 wards in 5 Belgian hospitals with recent (< 2 weeks prior to randomization) confirmed COVID-19 infection and acute respiratory failure defined as a PaO2/FiO2 below 350 mmHg or SpO2 below 93% on minimal 2 L/min supplemental oxygen. Patients were excluded from the trial in case of (1) known serious allergic reactions to yeast-derived products, (2) lithium carbonate therapy, (3) mechanical ventilation prior to randomization, (4) peripheral white blood cell count above 25.000/μL and/or active myeloid malignancy, (5) high dose systemic steroid therapy (> 20 mg methylprednisolone or equivalent), (6) enrolment in another investigational study, (7) pregnant or breastfeeding or (8) ferritin levels > 2000 μg/mL. Intervention and comparator Inhaled sargramostim 125 μg twice daily for 5 days in addition to standard care. Upon progression of disease requiring mechanical ventilation or to acute respiratory distress syndrome (ARDS) and initiation of mechanical ventilator support within the 5 day period, inhaled sargramostim will be replaced by intravenous sargramostim 125 μg/m2 body surface area once daily until the 5 day period is reached. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment. Intervention will be compared to standard of care. Subjects progressing to ARDS and requiring invasive mechanical ventilatory support, from day 6 onwards in the standard of care group will have the option (clinician's decision) to initiate IV sargramostim 125m μg/m2 body surface area once daily for 5 days. Main outcomes The primary endpoint of this intervention is measuring oxygenation after 5 days of inhaled (and intravenous) treatment through assessment of a change in pretreatment and post-treatment ratio of PaO2/FiO2 and through measurement of the P(A-a)O2 gradient (PAO2= Partial alveolar pressure of oxygen, PaO2=Partial arterial pressure of oxygen; FiO2= Fraction of inspired oxygen). Randomisation Patients will be randomized in a 1:1 ratio. Randomization will be done using REDCap (electronic IWRS system). Blinding (masking) In this open-label trial neither participants, caregivers, nor those assessing the outcomes will be blinded to group assignment. Numbers to be randomised (sample size) A total of 80 patients with confirmed COVID-19 and acute hypoxic respiratory failure will be enrolled, 40 in the active and 40 in the control group. Trial Status SARPAC protocol Version 2.0 (April 15 2020). Participant recruitment is ongoing in 5 Belgian Hospitals (i.e. University Hospital Ghent, AZ Sint-Jan Bruges, AZ Delta Roeselare, University Hospital Brussels and ZNA Middelheim Antwerp). Participant recruitment started on March 26th 2020. Given the current decline of the COVID-19 pandemic in Belgium, it is difficult to anticipate the rate of participant recruitment. Trial registration The trial was registered on Clinical Trials.gov on March 30th, 2020 (ClinicalTrials.gov Identifier: NCT04326920) - retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT04326920?term=sarpac&recrs=ab&draw=2&rank=1 and on EudraCT on March 24th, 2020 (Identifier: 2020-001254-22). Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource GM-CSF, Randomised controlled trial, protocol, COVID-19, sargramostim, leukine® Identifier An unambiguous reference to the resource within a given context DOI: 10.1186/s13063-020-04451-7 Source A related resource from which the described resource is derived Trials Publisher An entity responsible for making the resource available BMC Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine (General) https://socictopen.socict.org/files/original/c78ca657231992be0917d7c54e8a25f3.pdf ebc03a3aa3f195fbee8507865867b308 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource COVID-19: The Unseen Threat for the Healthcare Professionals Creator An entity primarily responsible for making the resource Kamath Sriganesh, G S Umamaheswara Rao Date A point or period of time associated with an event in the lifecycle of the resource 2020 Identifier An unambiguous reference to the resource within a given context DOI: 10.1055/s-0040-1712863 Source A related resource from which the described resource is derived Journal of Neurosciences in Rural Practice Publisher An entity responsible for making the resource available Thieme Publishers Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Neurosciences. Biological psychiatry. Neuropsychiatry https://socictopen.socict.org/files/original/440d7f8177e1b134034cce2cb5f49e63.pdf f172740895fb7bca64073708381d8576 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Longer-Term Forecasting of Excess Stock Returns—The Five-Year Case Creator An entity primarily responsible for making the resource Michael Scholz, Jens Perch Nielsen, Ioannis Kyriakou, Parastoo Mousavi Description An account of the resource Long-term return expectations or predictions play an important role in planning purposes and guidance of long-term investors. Five-year stock returns are less volatile around their geometric mean than returns of higher frequency, such as one-year returns. One would, therefore, expect models using the latter to better reduce the noise and beat the simple historical mean than models based on the former. However, this paper shows that the general tendency is surprisingly the opposite: long-term forecasts over five years have a similar or even better predictive power when compared to the one-year case. We consider a long list of economic predictors and benchmarks relevant for the long-term investor. Our predictive approach consists of adopting and implementing a fully nonparametric smoother with the covariates and the smoothing parameters chosen by cross-validation. We consistently find that long-term forecasting performs well and recommend drawing more attention to it when designing investment strategies for long-term investors. Furthermore, our preferred predictive model did stand the test of Covid-19 providing a relatively optimistic outlook in March 2020 when uncertainty was all around us with lockdown and facing an unknown new pandemic. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Prediction, benchmark, Cross-validation, stock returns, Long-term forecasts, Overlapping returns Identifier An unambiguous reference to the resource within a given context DOI: 10.3390/math8060927 Source A related resource from which the described resource is derived Mathematics Publisher An entity responsible for making the resource available MDPI AG Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Mathematics https://socictopen.socict.org/files/original/bc79e6cbcefbac722590961bdbbb048b.pdf f970777ec07db0b1cda0d5ca2154c05a Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019 Creator An entity primarily responsible for making the resource Lin Li, Qi Zhou, Jiancheng Xu Description An account of the resource Some patients with coronavirus disease 2019 (COVID-19) show abnormal changes in laboratory myocardial injury markers, suggesting that patients with myocardial injury have a higher mortality rate than those without myocardial injury. This article reviews the possible mechanism of myocardial injury in patients with COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the patients with COVID-19 in aspects of direct infection of myocardial injury, specific binding to functional receptors on cardiomyocytes, and immune-mediated myocardial injury. During hospitalization, the monitoring of laboratory myocardial injury markers in patients of COVID-19 should be strengthened. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Identifier An unambiguous reference to the resource within a given context DOI: 10.1155/2020/7413673 Source A related resource from which the described resource is derived BioMed Research International Publisher An entity responsible for making the resource available Hindawi Limited Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine https://socictopen.socict.org/files/original/802ab50b12bafeb5cad4fe77effcc71a.pdf 2d0e58da2d0b7f3327ee0bb8de5deb3d Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Air Microbiome and Pollution: Composition and Potential Effects on Human Health, Including SARS Coronavirus Infection Creator An entity primarily responsible for making the resource Karin Moelling, Felix Broecker Description An account of the resource Polluted air poses a significant threat to human health. Exposure to particulate matter (PM) and harmful gases contributes to cardiovascular and respiratory diseases, including allergies and obstructive lung disease. Air pollution may also be linked to cancer and reduced life expectancy. Uptake of PM has been shown to cause pathological changes in the intestinal microbiota in mice and humans. Less is known about the effects of pollution-associated microbiota on human health. Several recent studies described the microbiomes of urban and rural air samples, of the stratosphere and sand particles, which can be transported over long distances, as well as the air of indoor environments. Here, we summarize the current knowledge on airborne bacterial, viral, and fungal communities and discuss their potential consequences on human health. The current data suggest that bacterial pathogens are typically too sparse and short-lived in air to pose a significant risk for infecting healthy people. However, airborne fungal spores may exacerbate allergies and asthma. Little information is available on viruses including phages, and future studies are likely to detect known and novel viruses with a yet unknown impact on human health. Furthermore, varying experimental protocols have been employed in the recent microbiome and virome studies. Therefore, standardized methodologies will be required to allow for better comparisons between studies. Air pollution has been linked to more severe outcomes of SARS (severe acute respiratory syndrome) coronavirus (SARS-CoV) infections. This may have contributed to severe SARS-CoV-2 outbreaks, especially those in China, Northern Italy, Iran, and New York City. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Identifier An unambiguous reference to the resource within a given context DOI: 10.1155/2020/1646943 Source A related resource from which the described resource is derived Journal of Environmental and Public Health Publisher An entity responsible for making the resource available Hindawi Limited Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Public aspects of medicine